SARATOGA, Calif., March 26, 2026 (GLOBE NEWSWIRE) — CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent HighlightsFourth quarter 2025 revenue was $3.9 million, a 13% increase over the fourth quarter of 2024. Full year 2025 revenue was $13.6 million, a 15% increase compared to full year 2024. New accounts grew 16% in the fourth quarter of 2025 over the comparable quarter in 2024. Full year 2025 new accounts grew 21% compared to full year 2024. CapsoCam Plus® used by over 161,000 patients as of December 31, 2025. Submitted 510(k) application to the Food and Drug Administration (FDA) for its in-house developed AI-assisted module for...

Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026 Progressing enrollment for FDA-aligned Phase 3 trial in generalized myasthenia gravis (gMG) Positive progressive multiple sclerosis data underscore valuable pipeline-in-a-product opportunity with miv-cel Cash and cash equivalents of $279 million provide expected runway into 2028, funding SPS BLA filing, commercial launch, and Phase 3 gMG trial EMERYVILLE, Calif., March 26, 2026 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the fourth quarter and full year ended...

Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women’s Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today reported financial results for the year ended December 31, 2025, and provided a business update. “We are not a company that is just getting into women’s health. We are a women’s health biotech company – and we believe 2026 is the year investors will get to see what ten years of that commitment actually looks like. We built the company to change how women experience healthcare. That change...

RAMAT GAN, Israel, March 26, 2026 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced clinical updates and financial results for the year ended December 31, 2025 and early 2026. Advances in Clinical Programs Pancreatic Cancer Phase 2a study in pancreatic cancer met its primary endpoint of safety in heavily pretreated patients. The study continues to follow patients for overall survival, with data maturing over time; currently more than 30% of patients are alive at last data cut-off. Hepatocellular Carcinoma (HCC)A  patient with advanced HCC, treated with Namodenoson has reached an overall survival of more than  9 years with complete response to treatment. The...

FREMONT, Calif., March 26, 2026 (GLOBE NEWSWIRE) — Interlink Electronics, Inc. (Nasdaq: LINK) (“Interlink” or the “Company”), a global leader in sensor technology and printed electronic solutions, today reported results for the fourth quarter ended December 31, 2025. Q4 2025 and Recent HighlightsRecently began volume production of a custom piezoelectric sensor solution now deployed in the rapidly expanding autonomous vehicle market. Now shipping a second-generation custom FSR solution for a leading robotic-assisted surgery platform. Continued expansion of our presence as a trusted provider of printed electrode solutions in the healthcare diagnostics market. Added two Senior Business Development Directors in January 2026 to drive organic growth in North America and Europe. Successful conversion of our preferred stock into common...

PRESS RELEASE 2025 Full-year revenues increased by 18.4% year over year, reaching $2.63 billion. Net income attributable to Formula shareholders reached $606.5 million following the completion of Sapiens’ acquisition by Advent. OR YEHUDA, Israel, March 26, 2026 (GLOBE NEWSWIRE) — Formula Systems (1985) Ltd. (Nasdaq and TASE: FORTY) (“Formula” or the “Company”), a global information technology group engaged, through its subsidiaries and affiliates, in providing software consulting services and computer-based business solutions and developing proprietary software products, today announced its fourth quarter and full year 2025 results of operations. Financial Highlights for the Fourth Quarter Ended December 31, 2025On August 13, 2025, Sapiens International Corporation N.V. (hereafter, “Sapiens”), a subsidiary of the Company at...

Delivers 12.3% Sales Growth, Driven by Strong Demand for the Company’s Defense Solutions KFAR SABA, Israel, March 26, 2026 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, today announced its financial results for year ended December 31, 2025. Key Highlights of ParaZero’s Achievements in 2025 & Recent Highlights:Sales increased by 12.3% to $1,046,644 for the year ended December 31, 2025, primarily driven by newly developed products in the defense sector Three purchase orders received from Israeli defense entities for DefendAir Counter-Unmanned Aerial Systems solutions reinforcing trust and operational reliance on ParaZero’s DefendAir platform. Cash...

EDMONTON, Alberta, March 26, 2026 (GLOBE NEWSWIRE) — Servus Credit Union Ltd. (Servus) announced today its financial results for the first quarter of fiscal 2026, reporting income before taxes and patronage of $110 million, an increase of over $42 million, or 62 per cent, compared with the same period last year. The significant year-over-year growth reflects strong net interest margin and non-interest income performance. Additionally, during the quarter, Servus achieved a significant milestone in its wealth business, surpassing $10 billion in wealth assets under management. Total assets under management for Servus overall now stand at $40.2 billion, further reinforcing Servus’s position as Canada’s largest credit union. “This quarter marks the first year-over-year comparison since the close of our merger and the momentum we’re...

FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for the treatment of Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tractMeiraGTx to hold a program update and present long-term data for AAV2-hAQP1 program for the treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16th, 2026LONDON and NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) — MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the fourth quarter and full-year ended December 31, 2025, and provided a corporate update. “We are delighted to have been awarded Breakthrough Designation for our AAV2-hAQP1 treatment for Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the...

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Lead clinical candidate IND filing in Acumen’s Enhanced Brain Delivery (EBDTM) program targeted for mid-2027, following strong preclinical data and $35.75 million private placement to advance candidates in AβO-selective EBD portfolio Cash, cash equivalents and marketable securities of $116.9 million as of Dec. 31, 2025, expected to support current clinical and operational activities into early 2027  Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) —  Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target...